# Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC

> **NCT02639858** · PHASE2 · UNKNOWN · sponsor: **Samyang Biopharmaceuticals Corporation** · enrollment: 31 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Docetaxel-PM

## Key facts

- **NCT ID:** NCT02639858
- **Lead sponsor:** Samyang Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2017-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639858, "Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02639858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*